157 related articles for article (PubMed ID: 12504792)
21. Pyridoxal isonicotinoyl hydrazone and its analogues.
Buss JL; Hermes-Lima M; Ponka P
Adv Exp Med Biol; 2002; 509():205-29. PubMed ID: 12572996
[No Abstract] [Full Text] [Related]
22. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilize iron from reticulocytes in vitro: reappraisal of reported partition coefficients.
Edward JT; Chubb FL; Sangster J
Can J Physiol Pharmacol; 1997 Dec; 75(12):1362-8. PubMed ID: 9534947
[TBL] [Abstract][Full Text] [Related]
23. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
Link G; Ponka P; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
Blood; 2003 May; 101(10):4172-9. PubMed ID: 12511418
[TBL] [Abstract][Full Text] [Related]
24. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture.
Baker E; Vitolo ML; Webb J
Biochem Pharmacol; 1985 Sep; 34(17):3011-7. PubMed ID: 4038321
[TBL] [Abstract][Full Text] [Related]
25. Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity.
Simunek T; Sterba M; Popelova O; Kaiserova H; Potacova A; Adamcova M; Mazurova Y; Ponka P; Gersl V
Hemoglobin; 2008; 32(1-2):207-15. PubMed ID: 18274998
[TBL] [Abstract][Full Text] [Related]
26. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron.
Richardson DR; Mouralian C; Ponka P; Becker E
Biochim Biophys Acta; 2001 May; 1536(2-3):133-40. PubMed ID: 11406348
[TBL] [Abstract][Full Text] [Related]
27. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
Darnell G; Richardson DR
Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal.
Hershko C; Avramovici-Grisaru S; Link G; Gelfand L; Sarel S
J Lab Clin Med; 1981 Jul; 98(1):99-108. PubMed ID: 7252329
[TBL] [Abstract][Full Text] [Related]
29. The role of oxidative stress in the toxicity of pyridoxal isonicotinoyl hydrazone (PIH) analogues.
Buss JL; Neuzil J; Ponka P
Biochem Soc Trans; 2002 Aug; 30(4):755-7. PubMed ID: 12196187
[TBL] [Abstract][Full Text] [Related]
30. Effect of pyridoxal isonicotinoyl hydrazone and analogs on iron metabolism in hepatocytes and macrophages in culture.
Richardson D; Baker E; Ponka P; Wilairat P; Vitolo ML; Webb J
Birth Defects Orig Artic Ser; 1988; 23(5B):81-8. PubMed ID: 3390577
[No Abstract] [Full Text] [Related]
31. Pyridoxal isonicotinoyl hydrazone (PIH): a promising new iron chelator.
Webb J; Vitolo ML
Birth Defects Orig Artic Ser; 1988; 23(5B):63-70. PubMed ID: 3291971
[No Abstract] [Full Text] [Related]
32. The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) protects plasmid pUC-18 DNA against *OH-mediated strand breaks.
Hermes-Lima M; Nagy E; Ponka P; Schulman HM
Free Radic Biol Med; 1998 Nov; 25(8):875-80. PubMed ID: 9840731
[TBL] [Abstract][Full Text] [Related]
33. Pyridoxal isonicotinoyl hydrazone (PIH) prevents copper-mediated in vitro free radical formation.
Hermes-Lima M; Gonçalves MS; Andrade RG
Mol Cell Biochem; 2001 Dec; 228(1-2):73-82. PubMed ID: 11855743
[TBL] [Abstract][Full Text] [Related]
34. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease.
Richardson DR; Ponka P
J Lab Clin Med; 1998 Apr; 131(4):306-15. PubMed ID: 9579383
[TBL] [Abstract][Full Text] [Related]
35. Pyridoxal Isonicotinoyl Hydrazone Improves Neurological Recovery by Attenuating Ferroptosis and Inflammation in Cerebral Hemorrhagic Mice.
Zhang H; Wen M; Chen J; Yao C; Lin X; Lin Z; Ru J; Zhuge Q; Yang S
Biomed Res Int; 2021; 2021():9916328. PubMed ID: 34541001
[TBL] [Abstract][Full Text] [Related]
36. Pyridoxal isonicotinoyl hydrazone inhibits iron-induced ascorbate oxidation and ascorbyl radical formation.
MaurÃcio AQ; Lopes GK; Gomes CS; Oliveira RG; Alonso A; Hermes-Lima M
Biochim Biophys Acta; 2003 Mar; 1620(1-3):15-24. PubMed ID: 12595068
[TBL] [Abstract][Full Text] [Related]
37. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression.
Gao J; Richardson DR
Blood; 2001 Aug; 98(3):842-50. PubMed ID: 11468187
[TBL] [Abstract][Full Text] [Related]
38. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone.
Cikrt M; Ponka P; Necas E; Neuwirt J
Br J Haematol; 1980 Jun; 45(2):275-83. PubMed ID: 7437326
[TBL] [Abstract][Full Text] [Related]
39. The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) and its analogues prevent damage to 2-deoxyribose mediated by ferric iron plus ascorbate.
Hermes-Lima M; Ponka P; Schulman HM
Biochim Biophys Acta; 2000 Oct; 1523(2-3):154-60. PubMed ID: 11042379
[TBL] [Abstract][Full Text] [Related]
40. Chemical studies of pyridoxal isonicotinoyl hydrazone relevant to its clinical evaluation.
Vitolo ML; Clare BW; Hefter GT; Webb J
Birth Defects Orig Artic Ser; 1988; 23(5B):71-9. PubMed ID: 3390576
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
